We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$4.59B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+34.33%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.17B
AUM Growth
+$193M
(+4.9%)
Cap. Flow
-$193M
Cap. Flow
% of AUM
-4.62%
Top 10 Holdings %
Top 10 Hldgs %
41.32%
Holding
120
New
16
Increased
14
Reduced
24
Closed
15
Top Buys
| 1 |
Danaher
DHR
|
+$52.4M |
| 2 |
Cigna
CI
|
+$48.2M |
| 3 |
United Therapeutics
UTHR
|
+$38.6M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$29.4M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$28.9M |
Top Sells
| 1 |
UnitedHealth
UNH
|
+$105M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$93.6M |
| 3 |
Tenet Healthcare
THC
|
+$81.8M |
| 4 |
Boston Scientific
BSX
|
+$39.8M |
| 5 |
Cytokinetics
CYTK
|
+$35.6M |
Sector Composition
| 1 | Healthcare | 99.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Corvus Pharmaceuticals
CRVS
$1.26B
| $52.8M | 1.27% |
7,165,006
| – | – |
|
|
APLS
27
DELISTED
Apellis Pharmaceuticals
APLS
| $52.6M | 1.26% |
2,323,368
+841,068
| +57% | +$19.6M |
|
|
28
Danaher
DHR
$142B
| $52.2M | 1.25% |
+263,100
| New | +$52.4M |
|
29
Neurocrine Biosciences
NBIX
$17.4B
| $49.6M | 1.19% |
353,640
-84,900
| -19% | -$11.5M |
|
|
30
United Therapeutics
UTHR
$22.6B
| $48.2M | 1.16% |
+114,900
| New | +$38.6M |
|
|
31
Cigna
CI
$80.4B
| $46.9M | 1.13% |
+162,800
| New | +$48.2M |
|
32
Crinetics Pharmaceuticals
CRNX
$8.89B
| $45.8M | 1.1% |
1,099,000
-50,000
| -4% | -$1.6M |
|
|
33
Oric Pharmaceuticals
ORIC
$1.11B
| $43.7M | 1.05% |
3,641,756
+2,742,475
| +305% | +$28.9M |
|
34
Janux Therapeutics
JANX
$976M
| $43.2M | 1.04% |
1,766,100
+555,800
| +46% | +$13.5M |
|
35
Roivant Sciences
ROIV
$25.1B
| $41.1M | 0.99% |
2,714,798
-64,629
| -2% | -$800K |
|
|
36
Ascendis Pharma A/S
ASND
$17.5B
| $38.2M | 0.92% |
191,905
+157,505
| +458% | +$29.4M |
|
37
SI-BONE Inc
SIBN
$769M
| $38M | 0.91% |
2,578,979
| – | – |
|
|
SCPH
38
DELISTED
scPharmaceuticals
SCPH
| $34.4M | 0.82% |
6,059,528
| – | – |
|
|
ABVX
39
Abivax
ABVX
$11.9B
| $32.3M | 0.77% |
+380,000
| New | +$23.3M |
|
40
Structure Therapeutics
GPCR
$3.47B
| $31.9M | 0.77% |
1,139,300
-60,000
| -5% | -$1.2M |
|
41
Trevi Therapeutics
TRVI
$2.48B
| $30.3M | 0.73% |
3,308,400
| – | – |
|
42
Integer Holdings
ITGR
$3.23B
| $30M | 0.72% |
290,000
-143,400
| -33% | -$15.6M |
|
43
Dyne Therapeutics
DYN
$3.91B
| $29.3M | 0.7% |
2,314,184
+1,282,784
| +124% | +$14.6M |
|
|
RAPT
44
DELISTED
RAPT Therapeutics
RAPT
| $28M | 0.67% |
1,086,618
-555,288
| -34% | -$7.27M |
|
45
CytomX Therapeutics
CTMX
$790M
| $27M | 0.65% |
8,461,500
| – | – |
|
46
Neuropace
NPCE
$557M
| $27M | 0.65% |
2,614,184
| – | – |
|
47
uniQure
QURE
$2.8B
| $26.8M | 0.64% |
+458,500
| New | +$8.32M |
|
48
EyePoint Inc
EYPT
$1.15B
| $25.6M | 0.61% |
+1,796,000
| New | +$20.7M |
|
|
AKRO
49
DELISTED
Akero Therapeutics
AKRO
| $25M | 0.6% |
526,200
+314,900
| +149% | +$15.2M |
|
50
ADC Therapeutics
ADCT
$158M
| $23.6M | 0.57% |
5,907,351
| – | – |
|
Similar funds
CGI
LNWTC
SCM
AG
SCM
SV
ANTB
ECM